<TABLE>
IGI, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(thousands, except per share information)
Three months ended March 31,
1997 1996
---- ----
<CAPTION>
<S> <C> <C>
Net sales $ 9,479 $ 8,626
Cost of sales 4,142 3,845
------- -------
Gross profit 5,337 4,781
Selling, general and administrative
expenses 3,806 3,372
Research and development expenses 489 538
------- -------
Operating profit 1,042 872
Interest expense, net 475 478
------- -------
Income before provision for income
taxes 567 394
Provision for income taxes 204 118
------- -------
Net income $ 363 $ 276
======= =======
Net income per common and common
equivalent share $ .04 $ .03
======= =======
Average number of common and common
equivalent shares 9,605 9,629
======= =======
The accompanying notes are an integral part
of the consolidated financial statements.
</TABLE>
<PAGE>
<TABLE>
IGI, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Amounts in thousands)
March 31, December 31,
ASSETS 1997 1996
---- ----
<CAPTION>
<S> <C> <C>
Current assets:
Cash and equivalents $ 183 $ 317
Accounts receivable, less allowance for
doubtful accounts of $288 and $238
respectively 8,863 8,709
Receivable due under royalty agreement - 1,000
Inventories 9,427 9,357
Current deferred taxes, net - 54
Prepaid and other current assets 902 1,163
------- -------
Total current assets 19,375 20,600
------- -------
Notes receivable, less current maturities 168 162
------- -------
Property, plant and equipment - at cost:
Land 625 625
Buildings 9,488 9,382
Machinery and equipment 9,341 9,241
------- -------
19,454 19,248
Less accumulated depreciation (9,355) (9,121)
------- -------
10,099 10,127
------- -------
Deferred income taxes 2,977 3,159
Other assets 676 746
------- -------
$33,295 $34,794
======= =======
Continued
The accompanying notes are an integral part
of the consolidated financial statements.
</TABLE>
<PAGE>
<TABLE>
IGI, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS, Continued
(Unaudited)
(Amounts in thousands, except share information)
March, 31, December 31,
LIABILITIES AND STOCKHOLDERS' EQUITY 1997 1996
---- ----
<CAPTION>
<S> <C> <C>
Current liabilities:
Note payable to bank $ 9,044 $ 9,642
Current maturities of long-term debt 3,443 3,443
Accounts payable 2,378 2,665
Accrued payroll 163 470
Other accrued expenses 880 675
Income taxes payable - 38
------- -------
Total current liabilities 15,908 16,933
------- -------
Long-term debt, less current maturities 6,032 6,893
------- -------
Deferred income from royalty contract 1,000 1,000
------- -------
Commitments and contingencies
Stockholders' equity:
Common stock, $.01 par value, 30,000,000
shares authorized; 9,572,681 shares issued 96 96
Stock subscribed - 175
Additional paid-in capital 19,071 19,115
Deficit (6,422) (6,785)
------- -------
12,745 12,601
Less treasury stock; 139,082 and 164,082 shares
at cost, in 1997 and 1996, respectively (2,275) (2,518)
Stockholders' notes receivable (115) (115)
------- -------
Total stockholders' equity 10,355 9,968
------- -------
$33,295 $34,794
======= =======
The accompanying notes are an integral part
of the consolidated financial statements.
</TABLE>
<PAGE>
<TABLE>
IGI, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Amounts in thousands)
Three months ended March 31,
1997 1996
<CAPTION>
<S> <C> <C>
Cash flows from operating activities:
Net income $ 363 $ 276
Reconciliation of net income to net cash
provided (used) by operating activities:
Depreciation and amortization 267 259
Provision for losses on accounts receivable
and inventories 100 30
Issuance of stock to 401(k) plan - 28
Credit for deferred income taxes 182 -
Stock option compensation expense 24 -
Changes in operating assets and liabilities:
Accounts receivable (204) (183)
Receivable due under royalty agreement 1,000 -
Inventories (120) 104
Prepaid and other assets 315 (529)
Accounts payable and accrued expenses (389) (328)
Income taxes payable or refundable (38) 114
------ ------
Net cash provided (used) by operating activities 1,500 (229)
------ ------
Cash flows from investing activities:
Capital expenditures, net (206) (308)
Decrease (increase) in other assets 31 (257)
------ ------
Net cash used by investing activities: (175) (565)
------ ------
Cash flows from financing activities:
Net borrowings under line of credit agreements (598) 777
Payments of long-term debt (861) (4)
------ ------
Net cash (used) provided from financing
activities: (1,459) 773
------ ------
Net increase in cash and equivalents (134) (21)
Cash and equivalents at beginning of year 317 169
------ ------
Cash and equivalents at March 31, 1997 and 1996 $ 183 $ 148
====== ======
The accompanying notes are an integral part
of the consolidated financial statements.
</TABLE>
<PAGE>
IGI, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Basis of Presentation
---------------------
The accompanying consolidated financial statements have been prepared by
IGI, Inc. without audit, pursuant to the rules and regulations of the
Securities and Exchange Commission, and reflect all adjustments which, in the
opinion of management, are necessary for a fair statement of the results for
the interim periods presented. All such adjustments are of a normal
recurring nature.
Certain information in footnote disclosures normally included in
financial statements prepared in accordance with generally accepted
accounting principles has been condensed or omitted pursuant to such rules
and regulations, although the Company believes the disclosures are adequate
to make the information presented not misleading. These financial statements
should be read in conjunction with the financial statements and the notes
thereto included in the Company's Annual Report on Form 10-K for the year
ended December 31, 1996.
2. Net Income Per Common Share
---------------------------
Net income per share of common stock is computed by dividing net income
by the weighted average number of shares of common stock and common stock
equivalents, if dilutive, outstanding during the three month periods ended
March 31, 1997 and 1996. Common stock equivalents include shares issuable
upon the exercise of dilutive common stock options. Fully diluted earnings
per share approximate primary earnings per share.
3. Inventories
-----------
Inventories are valued at the lower of cost or market using the last-in,
first-out (LIFO) method and consist of the following: (Amounts in thousands)
<TABLE>
March 31, 1997 December 31, 1996
-------------- -----------------
<CAPTION>
<S> <C> <C>
Finished Goods $3,342 $3,570
Work-in-process 3,166 2,975
Raw Materials 2,919 2,812
------ ------
Total $9,427 $9,357
====== ======
</TABLE>
Inventory values computed under the first-in, first-out (FIFO) method
approximate the values determined using LIFO.
<PAGE>
IGI, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, continued
(Unaudited)
4. Business Segments
-----------------
Summary operating results for the Company's Animal Health and Consumer
Products segments for the three month periods ended March 31, 1997 and 1996
appear below: (Amounts in thousands)
<TABLE>
Animal Consumer
1997 Health Products Corporate Consolidated
- ---- ------ -------- --------- ------------
<CAPTION>
<S> <C> <C> <C> <C>
Net sales $ 8,206 $ 1,273 $ - $ 9,479
Gross profit 4,603 734 - 5,337
Operating profit (loss) 2,058 60 (1,076) 1,042
1996
- ----
Net sales $ 8,010 $ 616 $ - $ 8,626
Gross profit 4,267 514 - 4,781
Operating profit (loss) 1,981 (300) (809) 872
</TABLE>
<PAGE>
IGI, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
RESULTS OF OPERATIONS
- ---------------------
Three months ended March 31, 1997 compared to March 31, 1996
- ------------------------------------------------------------
The Company had net income of $363,000 or $.04 per share, an increase of
$87,000 or 32% over the first quarter of 1996. This increase is primarily
attributable to the operations of the Company's Consumer Products segment
which had 1997 operating profits of $60,000, before corporate expenses,
compared to an operating loss of $300,000 in the first quarter of 1996.
This improvement in profitability was due to a substantial increase in
Consumer Products sales and a reduction in selling and marketing costs related
to the Nova Skin Care product line, which is being marketed by Glaxo under a
license and supply agreement. Operating profit for the quarter was
$1,042,000, an increase of $170,000 or 20%.
Sales increased $853,000 or 10%. Consumer Product sales increased
$657,000 or 107% over the first quarter of 1996 and accounted for 13% of
total sales in 1997 compared to 7% of total sales in 1996. This increase is
due to increased product sales to Estee Lauder and introductory product sales
to Glaxo. The Company also recorded a license payment from Kimberly Clark
during the first quarter for exclusive rights for a Novasome encapsulated
industrial hand cleaner. Under the terms of the agreement, the Company will
manufacture initial product requirements and sell proprietary equipment to
enable Kimberly Clark to commence production. In addition, the Company recorded
its first royalty income under the Glaxo agreement during the first quarter.
Animal Health product sales increased $196,000 or 2%. Sales of the Company's
companion pet products (EVSCO and Tomlyn) increased $325,000 or 15% in domestic
markets. International sales of Animal Health products increased $72,000 or
2% over the first quarter of 1996. These increases were offset, in part, by a
$202,000 or 9% decrease in domestic sales of the Company's poultry vaccine
products. This decrease relates principally to price erosion for certain
products.
Gross profit increased $556,000 or 12% due principally to the higher
sales volume. Excluding license payments, gross profit as a percentage of
sales was 55%, the same as the first quarter of 1996.
Selling, general and administrative expenses increased $434,000 or 13%.
As a percentage of sales, the expenses were 40% compared to 39% in 1996.
This increase relates to variable costs associated with the increased sales
volume. During the first quarter of 1996, the Company's administrative
expenses were reduced by $120,000 which was charged to a former subsidiary
under the terms of a transitional service agreement. This agreement ended
June 30, 1996. During the first quarter of 1997, the Company reduced its
workforce related to the Nova Skin Care product line. The Company expects to
be paid by Glaxo for the majority of the Company's costs associated with these
products in the future. The Company had expenses related to terminated
employees during the first quarter of approximately $145,000.
Research and development expenses decreased $49,000 or 9%. The Company
has curtailed certain development projects, and these projects will be
re-commenced unless the Company enters into collaborative agreements with
industry partners under which the partner will fund the research efforts.
Net interest expense decreased $3,000 due to reduced borrowings.
<PAGE>
IGI, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
Liquidity and Capital Resources
- -------------------------------
The Company's operating activities provided cash of $1,500,000 during
the three month period ended March 31 1997. The principle sources of this
cash were the receipt of $1,000,000 from Glaxo Wellcome under a license and
supply agreement and net income of $363,000. The Company used $175,000 for
investing activities principally for capital expenditures. The Company
repaid $1,459,000 of bank loans with the cash generated by its operations.
Accounts receivable turnover ratio was 4.32, compared to 4.09 for the year
ended December 31, 1996. Accounts receivable balances due from Mexico and Latin
America were 25% compared to 28% at December 31, 1996. The inventory
turnover ratio for the first quarter of 1997 was 1.76, compared to 1.75 for
the year ended December 31, 1996.
At May 5, 1997, the Company had $1,245,000 of available borrowing
capacity under its $10 million working capital line of credit and no
borrowings available under the revolving credit facility. The Company has
quarterly maturities of $857,000 payable under the revolving credit facility.
The Company believes that cash generated from operating activities as well as
available borrowings under its working capital line of credit facility will
be sufficient to meet these obligations. However, over the longer term, the
Company will require additional funds for its business. No assurance can be
given that the Company will be successful in obtaining the required funds,
and, if not, the Company may be required to cut back on certain of its
operations or otherwise modify its business strategy.
<PAGE>
IGI, INC. AND SUBSIDIARIES
Part II OTHER INFORMATION
Item 1 - Legal Proceedings
- --------------------------
None
Item 2 - Changes in Securities
- ------------------------------
The constituent instruments defining the rights of the holders of any class
of securities were not modified nor were the rights evidenced by any class of
registered securities materially limited or qualified during the period covered
by this report.
Item 3 - Defaults Upon Senior Securities
- ----------------------------------------
No defaults occurred during the period covered in this report.
Item 4 - Submission of Matters to a Vote of Security Holders
- ------------------------------------------------------------
None
Item 5 - Other information
- --------------------------
None
Item 6 - Exhibits and Reports on Form 8-K
- -----------------------------------------
(a) Exhibits:
--------
Exhibit 11 - Computation of Net Income Per Common Share
Exhibit 27 - Financial Data Schedule
(b) Reports on Form 8-K
-------------------
None
<PAGE>
IGI, INC. AND SUBSIDIARIES
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
IGI, INC.
(Registrant)
Date: May 9, 1997
By:
-----------------
Donald J. MacPhee
Vice President (Principal
Financial and Accounting Officer)
<TABLE>
EXHIBIT 11
IGI, INC. AND SUBSIDIARIES
COMPUTATION OF NET INCOME PER COMMON SHARE
(Unaudited)
(thousands, except per share information)
<CAPTION>
Three months ended
March 31,
1997 1996
---- ----
<S> <C> <C>
Net income for primary
earnings per share $ 363 $ 276
====== ======
Weighted average shares outstanding 9,431 9,266
Common stock equivalents
(net of common stock deemed
reacquired) based on
average market price 174 363
------ ------
Total equivalent shares for
primary computation 9,605 9,629
======= ======
Per Share Amounts:
Primary:
Net income $ .04 $ .03
===== =====
Fully diluted earnings per share have been omitted as they approximate primary
earnings per share.
</TABLE>
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-97
<PERIOD-END> MAR-31-97
<CASH> 183
<SECURITIES> 0
<RECEIVABLES> 8,863
<ALLOWANCES> 288
<INVENTORY> 9,427
<CURRENT-ASSETS> 19,357
<PP&E> 19,454
<DEPRECIATION> 9,355
<TOTAL-ASSETS> 33,295
<CURRENT-LIABILITIES> 15,908
<BONDS> 0
<COMMON> 96
0
0
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 33,295
<SALES> 9,479
<TOTAL-REVENUES> 9,479
<CGS> 4,142
<TOTAL-COSTS> 4,295
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 475
<INCOME-PRETAX> 567
<INCOME-TAX> 204
<INCOME-CONTINUING> 363
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 363
<EPS-PRIMARY> .04
<EPS-DILUTED> .04
</TABLE>
